Picture1.png
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
August 03, 2023 07:00 ET | Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...
Picture1.png
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
July 19, 2023 07:00 ET | Autolus Therapeutics plc
- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program LONDON,...
Picture1.png
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
July 18, 2023 07:00 ET | Autolus Therapeutics plc
LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Picture1.png
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
July 06, 2023 07:00 ET | Autolus Therapeutics plc
Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years...
Picture1.png
Autolus Therapeutics announces publication in Cancer Immunology Research
June 27, 2023 07:00 ET | Autolus Therapeutics plc
LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Picture1.png
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
June 20, 2023 07:00 ET | Autolus Therapeutics plc
LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Picture1.png
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
June 16, 2023 07:00 ET | Autolus Therapeutics plc
At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A)Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months...
Picture1.png
Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023
June 06, 2023 07:00 ET | Autolus Therapeutics plc
LONDON, June 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, has posted...
Picture1.png
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
June 02, 2023 07:00 ET | Autolus Therapeutics plc
76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysisPotential best in class...
Picture1.png
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA
May 12, 2023 07:00 ET | Autolus Therapeutics plc
LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...